摘要
In order to clarify the pre-exist immunity background of different human coronaviruses(HCoV),this study investigated the positive rate of spike(S)protein antibodies of HCoV,including HCoV-severe acute respiratory syndrome(SARS)-associated coronavirus(SARS-CoV-1),severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),Middle East respiratory syndrome coronavirus(MERS-CoV),HCoV-229E,HCoV-NL63,HCoV-HKU1 and HCoV-OC43,before and after the Coronavirus Disease 2019(COVID-19)outbreak.We utilized pseu-dotyped virus-based neutralization assays(PBNA)or enzyme-linked immunosorbent assays(ELISA)to detect antibody levels against HCoV in serum samples collected in 2009-2010 and 2023.The PBNA results showed that neutralizing antibodies against SARS-CoV-1 and the MERS-CoV were negative.In the serum samples from 2009 to 2010,neutralizing antibodies against SARS-CoV-2(D614G)were negative,whereas in the serum sam-ples from 2023,73 samples(73%)showed neutralizing reactions with the SARS-CoV-2 D614G strain,96 sam-ples(96%)with the BA.5 strain,and 91 samples(91%)with the BF.7 strain.Among pre-COVID-19 samples,33%(33/100)showed neutralizing reactions with HCoV-229E and 63%(63/100)with HCoV-NL63.Among post-COVID-19 samples,50%(50/100)showed neutralizing reactions with HCoV-229E and 49%(49/100)with HCoV-NL63.Due to the different receptors of alpha coronavirus genus compared to other beta coron-avirus genus,neutralizing antibodies against HCoV-OC43 and HCoV-HKU1 virus cannot be detected by con-structing corresponding pseudotyped virus.Binding antibodies against HCoV-OC43 and HCoV-HKU1 virus were detected using ELISA.The results revealed that among pre-COVID-19 samples,83%(83/100)and 45%(45/100)had binding activity with HCoV-OC43 and HCoV-HKU1,respectively.Among post-COVID-19 samples,100%(100/100)and 81%(81/100)had binding activity with HCoV-0C43 and HCoV-HKU1,respectively.
基金
supported by National Key Research and Development Program of China:Analysis of Omicron Variants and Research of Prevention and Control(No.2023YFC3041500)
National Natural Science Foundation of China:Research on in vivo and in vitro Efficacy Evaluation Technology for Novel Coronavirus Vaccine Standardization(No.82073621)
State Key Laboratory of Drug Regulatory Science:Establishment of mouse infection model by influenza and SARS-CoV-2 pseudovirus(No.2023SKDLS0112).
